Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design Conference Paper uri icon

Overview

MeSH Major

  • Arthritis
  • Biomarkers
  • Evidence-Based Medicine
  • Joints

abstract

  • The OMERACT 9 Soluble Biomarker Group has successfully formulated a levels of evidence scheme and a study design template that will provide guidance to conduct validation studies in the setting of soluble biomarkers proposed to replace the measurement of damage endpoints in RA, PsA, and AS.

publication date

  • August 2009

Research

keywords

  • Conference Paper

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.3899/jrheum090347

PubMed ID

  • 19671814

Additional Document Info

start page

  • 1792

end page

  • 9

volume

  • 36

number

  • 8